Therapeutic Approaches to Hidden Hearing Loss with Celia Belline, CEO of Cilcare скачать в хорошем качестве

Therapeutic Approaches to Hidden Hearing Loss with Celia Belline, CEO of Cilcare

What if we could treat hearing loss before it shows up on a standard audiogram? Celia Belline, CEO and co-founder of Cilcare, shares progress on the company’s lead compound, CIL001, developed to treat cochlear synaptopathy—often referred to as hidden hearing loss. A Phase 2A clinical trial is planned to begin later this year, targeting individuals with type 2 diabetes who are more likely to present early signs of the condition. The conversation explores how early-stage auditory synaptic damage may contribute to both hearing difficulties in noise and tinnitus, why timely intervention matters, and what’s ahead for the hearing therapeutics field. 🔗 Learn more: https://www.cilcare.com Be sure to subscribe to our channel for the latest episodes each week and follow This Week in Hearing on LinkedIn, Instagram and X. https://x.com/WeekinHearing   / thisweekinhearing     / this-week-in-hearing   https://hearinghealthmatters.org/this... Audio podcast can be found on all major platforms, including Apple & Spotify: https://podcasters.spotify.com/pod/sh... TIMESTAMPS 00:00 Introduction 00:56 Background - Cilcare 02:19 CIL001 trial to treat cochlear synaptopathy 04:24 DIAMANT Study 05:21 Understanding cochlear synaptopathy (hidden hearing loss) 07:49 How treatment is administered 11:50 Future vision of hearing therapeutics